Shalu's practice focuses on complex litigation in the intellectual property space across almost all technologies, including biotechnology, ANDA, FinTech, blockchain/smart contracts, software, mobile applications, pharmaceuticals, and medical devices. His technical background and scientific training allow him to understand these technologies and impart reasoned advice. He also provides strategic counseling and guidance to clients ranging from start-ups to Fortune 50 companies.
Shalu has litigated across the country at all levels including District Courts, the Federal Court of Claims, the International Trade Commission, the PTAB, the U.S. Court of Appeals for the Federal Circuit, and has also had a case heard by the United States Supreme Court. Shalu has particular expertise in “Section 337” cases at the ITC, having been involved in over 20 matters relating to patent, trademark, and trade secret disputes of behalf of both complainants, respondents, and third-parties. He has successfully obtained general and limited exclusion orders on behalf of his clients and assisted in providing advisory opinions for clients seeking to import after exclusion orders. Shalu has been involved in nearly 100 intellectual property disputes.
Shalu also is very active in licensing and monetizing IP on behalf of clients. He has asserted large and cutting-edge patent portfolios for clients, resulting in significant licensing revenues, settlements, cross-licenses, and other business solutions. Shalu has drafted and negotiated a significant number of IP licenses for clients and conducted due diligence on patent portfolios for sales and acquisitions.
As part of his counseling practice, Shalu guides clients of all sizes on various legal issues that arise. He has drafted and negotiated numerous complex commercial agreements including SaaS, MSAs, NDAs, standstill, material transfer, and settlement agreements. He has also assisted with data privacy and compliance matters and policies for these clients, as well as other related corporate matters.
ANDA cases litigated: Trintellix (Vortioxetine), Dimethyl Fumarate (Tecfidera), Alogliptin (Kazano), Tafluprost (Zioptin), Epinephrine (Adrenalin), Risperdal (Risperidone), Clopidogrel (Plavix), Omeprazole (Prilosec), Amlodipine (Norvasc), Olanzapine (Zyprexa), Ondansetron (Zofran)